Healthcare / BiotechnologyNasdaqCM
$0.52
-0.05 (-8.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-38.4M · quality 79.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$20M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-138.8%
↓Gross Margin
99.5%
↑Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+0.6%
FCF CAGR
—
FCF margin
-288.1%
FCF / Net income
3.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.4M · net income $-7.6M · FCF $-27.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $9.4M | $9.4M | $10.9M | $10.0M | $10.2M | $10.6M | $10.8M | $10.0M | $10.4M | $9.9M | $7.5M | $7.9M | $9.8M | $15.0M | $17.0M | $14.8M | $16.0M | $8.6M |
| Net Income | $-7.6M | $-7.6M | $-43.4M | $-47.4M | $-56.7M | $-45.4M | $-29.9M | $-32.1M | $-32.6M | $-53.3M | $-60.4M | $-59.0M | $-18.7M | $-12.3M | $-16.4M | $-9.9M | $-4.4M | $-9.8M |
| EBITDA | $-5.2M | $-5.2M | $-42.6M | $-45.1M | $-51.7M | $-41.9M | $-24.8M | $-24.2M | $-29.2M | $-49.5M | $-57.8M | $-56.3M | $-15.7M | $-9.3M | $-18.5M | $-7.1M | $-5.0M | $-9.3M |
| EPS | — | — | -6.88 | -8.96 | -12.20 | 0.50 | -0.61 | -0.97 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 99.5% | 99.5% | 99.1% | 97.9% | 97.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -348.4% | -348.4% | -408.3% | -482.2% | -521.7% | -395.0% | -229.8% | -243.5% | -281.3% | -502.7% | -771.1% | -716.9% | -161.2% | -62.8% | -109.7% | -48.8% | -35.2% | -116.9% |
| Net Margin | -80.3% | -80.3% | -397.8% | -473.0% | -557.7% | -426.7% | -276.0% | -321.3% | -312.4% | -538.7% | -802.6% | -748.7% | -190.3% | -82.1% | -96.7% | -66.8% | -27.7% | -114.4% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.30 | 0.30 | -0.49 | 0.14 | 0.08 | — | — | 0.00 | -6.36 | 1.49 | 0.51 | 0.30 | 0.76 | 0.62 | 0.87 | — | — | — |
| Current Ratio | 1.22 | 1.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-27.2M | $-27.2M | $-39.6M | $-38.4M | $-54.8M | $-37.6M | $-26.4M | $-26.2M | $-30.1M | $-48.5M | $-36.1M | $-29.9M | $-16.9M | $-9.7M | $-15.3M | $-4.8M | $-1.9M | $-7.6M |
| Returns | ||||||||||||||||||
| ROE | -138.8% | -138.8% | 723.4% | -241.0% | -121.7% | -50.1% | -22.9% | 94.8% | 724.5% | -222.2% | -205.1% | -91.4% | -62.9% | -27.3% | -47.9% | -24.7% | -9.7% | -29.7% |
| Valuation | ||||||||||||||||||
| P/B | 1.24 | 1.24 | — | 3.39 | 1.30 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -13.4% | -13.4% | 8.8% | -1.4% | — | -1.7% | 8.3% | -4.1% | 5.4% | 31.5% | -4.5% | -20.0% | -34.4% | -11.6% | 15.0% | -7.7% | 86.3% | — |
| EPS Growth | — | — | 23.2% | 26.6% | — | 182.0% | 37.1% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-78.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.88 → n/d
Residual
-78.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.